1 completed, 1 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Peter Rossing: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study Kerendia (Finerenone, BAY94-8862), Placebo - Cardiovascular Autonomic Neuropathy, Type 2 Diabetes | Phase 2 | Recruiting | Peter Rossing | 100 | 2025-05-02 | 2025-05-25 |
| Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria Spironolactone, Placebo, Standard care - Diabetic Nephropathy, Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | Peter Rossing | 1777 | 2014-03-01 | 2018-12-21 |
Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Diabetic Neuropathies (1) · Diabetic Retinopathy (1) · Renal Insufficiency, Chronic (1)
Spironolactone (1) · Standard of Care (1) · finerenone (1)
Denmark (2) · Belgium (1) · Czechia (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · North Macedonia (1) · Spain (1) · United Kingdom (1)
Adriaan Kooy, MD (1) · Alberto Ortiz, MD (1) · Andreas Birkenfeld, MD (1) · Christian Delles, MD (1) · Gerjan Navis, MD (1) · Goce Spasovski, MD (1) · Ivan Rychlik, MD (1) · Joachim Beige, MD (1) · Joline Beulens, MD (1) · Marina Noutsou, MD (1) · Marjin Speeckaert, MD (1) · Matias Trillini, MD (1) · Peter Girman, MD (1)
PMID 26936907, PMID 29781558, PMID 32135136, PMID 33107592, PMID 36841085, PMID 41130701